Swiss consensus statement: Recommendations for optimising re-treatment with MabThera® (rituximab) in rheumatoid arthritis

Swiss Medical Weekly

Volumn 140, Issue JULY, 2010, Pages

  Dudler, Jean ^a   Finckh, Axel ^b   Kyburz, Diego ^c   Langenegger, Thomas ^d   Möller, Burkhard ^e   Schmiedel, Ute ^f   Walker, Ulrich A ^g  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Zuger Kantonsspital AG   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f Roche Pharma Schweiz AG   (Switzerland)

^g Rheumatologische Universitatsklinik und Poliklinik   (Switzerland)

Author keywords

Recommendations; Rheumatoid arthritis; Rituximab; Treatment response optimization

Indexed keywords

RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

CONSENSUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETREATMENT; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DOSE RESPONSE; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; FOLLOW UP; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RISK ASSESSMENT; STANDARD; SWITZERLAND; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FOLLOW-UP STUDIES; HUMANS; QUALITY OF LIFE; RETREATMENT; RISK ASSESSMENT; SWITZERLAND; TREATMENT OUTCOME;

EID: 84855980663     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2010.13073     Document Type: Review

References (23)

1. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-806. (Pubitemid 44497758)
2. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2008;59(6):785-93. (Pubitemid 351847560)
3. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. (Pubitemid 350262316)
4. Keystone EC. Efficacy and safety of repeat treatment courses of rituximab in RA patients with inadequate response to Tumor Necrosis Factor inhibitors: Long-term experience from the REFLEX study [abstract]. Arthritis Rheum. 2008.
5. Cohen S, E.C. K, Genovese MC, Emery P, Peterfy C, Tak PP, et al. Continued inhibition of structural damage in rheumatoid arthritis patients treated with rituximab at 2 years: REFLEX study (abstract). Ann Rheum Dis. 2008;67(Suppl II):189.
6. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2009;68(2):216-21.
7. Van Vollenhoven FR, Emery P, Bingham III CO, Keystone EC, Fleishmann RM, Furst DE, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558-67.
8. van Vollenhoven RF, Emery P, Bingham III CO, Keystone EC, Fleishmann RM, Furst DE, et al. Long-Term Safety of Rituximab: Long- Term Follow-up of the RA Clinical Trials and Retreatment Population [abstract]. Arthritis Rheum. 2009;60(Suppl 10):1952. DOI: 10.002/ art.27025.
9. Finckh A, Courvoisier D, Ciurea A, Brulhart L, Kyburz D, Scherer A, et al. Longterm treatment with RTX in RA: evidence for a learning curve by rheumatologists [abstract]. Ann Rheum Dis. 2009;68 (Suppl 3):438.
10. Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):143-50. (Pubitemid 46226045)
11. Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol. 2010;37(5):917-27.
12. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954-60.
13. Isaacs JD, Olech E, Tak PP, Deodhar A, Keystone E, Emery P, et al. Autoantibody-positive RA patients have enhanced clinical response to RTX when compared with seronegative patients [abstract]. Ann Rheum Dis. 2009;68(Suppl 3):442.
14. Moller B, Aeberli D, Eggli S, Fuhrer M, Vajtai I, Vogelin E, et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R62.
15. Ziswiler HR, Aeberli D, Villiger PM, Moller B. High-resolution ultrasound confirms reduced synovial hyperplasia following rituximab treatment in rheumatoid arthritis. Rheumatology. (Oxford). 2009;48(8):939-43.
16. Fleischman RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 2009;60(11):3225-28.
17. Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum. 2008;58(12):3657-64.
18. Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Horner EA, et al. Management of non-response to rituximab in rheumatoid arthritis: predictors and outcome of retreatment. Arthritis Rheum. 2010;doi 10.1002/art.27359.
19. Bykerk V. Unmet needs in rheumatoid arthritis. J Rheumatol Suppl. 2009;82:42-6.
20. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 1999;42(9):1854-60. (Pubitemid 30257749)
21. Keystone EC, Fleischmann R, Emery P, Dougados M, Baldassare AR, Armstrong GK, et al. Multiple Courses of Rituximab (RTX) Produce Sustained Efficacy in Patients (pts) with Rheumatoid Arthritis (RA) with An Inadequate Response (IR) to One or More TNF Inhibitors [abstract]. Arthritis Rheum. 2009;60(Suppl 10):1683. DOI: 10.002/ art.26757.
22. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, et al. Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent? Ann Rheum Dis. 2010;69(2):387-393.
23. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, et al. RTX in combination with MTX significantly inhibits joint damage and improves clinical outcomes in patients with early active RA who are naïve to MTX (IMAGE) [abstract]. Arthritis Rheum. 2009;60(Suppl 10):636 DOI: 10.1002/art.25716.